EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
The European Association of Urology (EAU) panel on Non-muscle-invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non-muscle-invasive Bladder Cancer.



To present the 2016 EAU guidelines on NMIBC.



A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned.



Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines).



These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice.



The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression.
Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic. Electronic address: marek.babjuk@lfmotol.cuni.cz.
Marko
M
Babjuk
Department of Urology, HELIOS Agnes-Karll-Krankenhaus, Bad Schwartau, Germany.
Andreas
A
Böhle
Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
Maximilian
M
Burger
Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Otakar
O
Capoun
Department of Surgery and Cancer, Imperial College London, UK; Department of Urology, Lister Hospital, East and North Hertfordshire NHS Trust, Stevenage, UK.
Daniel
D
Cohen
Department of Pathology, Hôpital La Pitié-Salpétrière, UPMC, Paris, France.
Eva M
EM
Compérat
Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Virginia
V
Hernández
Department of Urology, Hyvinkää Hospital, Hyvinkää, Finland.
Eero
E
Kaasinen
Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.
Joan
J
Palou
AP-HP, Hôpital La Pitié-Salpétrière, Service d'Urologie, Paris, France; UPMC University Paris 06, GRC5, ONCOTYPE-Uro, Institut Universitaire de Cancérologie, Paris, France.
Morgan
M
Rouprêt
Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Bas W G
BWG
van Rhijn
Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Shahrokh F
SF
Shariat
Department of Urology, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Viktor
V
Soukup
European Association of Urology Guidelines Office, Brussels, Belgium.
Richard J
RJ
Sylvester
Department of Urology, Medical University of Graz, Graz, Austria.
Richard
R
Zigeuner
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D015653:Cystectomy; D003558:Cystoscopy; D005060:Europe; D006801:Humans; D009130:Muscle, Smooth / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*; D014572:Urology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine
Bacillus Calmette-Guérin (BCG); Bladder cancer; Cystectomy; Diagnosis; European Association of Urology; Guidelines; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma